Announcement
12 Jan 2026
In January 2026, AbbVie announced reaching an agreement with the United States government to implement most-favoured-nation drug pricing for American patients.
Source
Sign in to access
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 05 Apr 2026
Local operations incentive
Recent update from 05 Apr 2026:
On 12 January 2026, AbbVie announced reaching an agreement with the U.S. Administration. Under the agreement, AbbVie will be exempt from tariffs and future pricing mandates for three years, in exch...
Sign in to see more
Updated: 05 Apr 2026
Tax or social insurance relief
Recent update from 05 Apr 2026:
On 12 January 2026, AbbVie announced reaching an agreement with the U.S. Administration. Under the agreement, AbbVie will be exempt from potential Section 232 tariffs and future pricing mandates fo...
Sign in to see more
Updated: 05 Apr 2026
Import tariff
Recent update from 05 Apr 2026:
On 12 January 2026, AbbVie announced reaching an agreement with the U.S. Administration providing the company with an exemption from potential Section 232 tariffs and future pricing mandates for th...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.